Human CD30 enzyme-linked immunoassay kit
| Specification | 96 Test |
|---|---|
| Sensitivity | 0.8 pg/ml (50 μl)；3.19 pg/ml (10 μl) |
| Standard Curve Range | 5.49~4000 pg/ml |
| Standard Curve Gradient | 7 Points/3 Folds |
| Number of Incubations | 2 |
| Sample Volume | 50 μl/10 μl |
| Type | Fully Ready-to-Use |
| Operation Duration | 120min |
| pg/ml | O.D. | Average | Corrected | |
|---|---|---|---|---|
| 0.00 | 0.0199 | 0.0202 | 0.0201 | |
| 5.49 | 0.0348 | 0.0353 | 0.0351 | 0.0150 |
| 16.46 | 0.0703 | 0.0685 | 0.0694 | 0.0494 |
| 49.38 | 0.1718 | 0.1691 | 0.1705 | 0.1504 |
| 148.15 | 0.4668 | 0.4436 | 0.4552 | 0.4352 |
| 444.44 | 1.2290 | 1.2290 | 1.2290 | 1.2090 |
| 1333.33 | 2.7640 | 2.8060 | 2.7850 | 2.7650 |
| 4000.00 | 4.3046 | 4.2674 | 4.2860 | 4.2660 |
Precision
| Intra-assay Precision | Inter-assay Precision | |||||
| Sample Number | S1 | S2 | S3 | S1 | S2 | S3 |
| 22 | 22 | 22 | 6 | 6 | 6 | |
| Average(pg/ml) | 87.5 | 398.2 | 1088.4 | 84.1 | 408.2 | 1263.3 |
| Standard Deviation | 5.2 | 21.2 | 81.8 | 2.9 | 25.6 | 82.2 |
| Coefficient of Variation(%) | 6.0 | 5.3 | 6.0 | 3.5 | 6.3 | 6.5 |
Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-assay Precision (Precision between assays) Three samples of known concentration were tested six times on one plate to assess intra-assay precision.
Spike Recovery
The spike recovery was evaluated by spiking 3 levels of human CD30 into health human serum sample. The un-spiked serum was used as blank in this experiment.
The recovery ranged from 83% to 98% with an overall mean recovery of 93%.
Sample Values
| Sample Matrix | Sample Evaluated | Range (pg/ml) | Detectable (%) | Mean of Detectable (pg/ml) |
|---|---|---|---|---|
| Serum | 30 | 643.28-1550.80 | 100 | 965.76 |
Serum/Plasma – Thirty samples from apparently healthy volunteers were evaluated for the presence of IL-12/IL-23 p40 in this assay. No medical histories were available for the donors.
Product Data Sheet
Background: CD30
CD30, also known as Ki-1 antigen and TNFRSF8, is a 120 kDa type I transmembrane glycoprotein belonging to the TNF receptor superfamily. Mature human CD30 consists of a 361 amino acid (aa) extracellular domain (ECD) with six cysteine-rich repeats, a 28 aa transmembrane segment, and a 188 aa cytoplasmic domain. In contrast, mouse and rat CD30 lack 90 aa of the ECD and contain only three cysteine-rich repeats. Within common regions of the ECD, human CD30 shares 53% and 49% aa sequence identity with mouse and rat CD30, respectively. Alternate splicing of human CD30 generates an isoform that includes only the C‑terminal 132 aa of the cytoplasmic domain. CD30 is normally expressed on antigen-stimulated Th cells and B cells. However, it is upregulated in Hodgkin’s disease (on Reed-Sternberg cells), other lymphomas, chronic inflammation, and autoimmunity. CD30 binds to CD30 Ligand/TNFSF8 which is expressed on activated Th cells, monocytes, granulocytes and medullary thymic epithelial cells. CD30 signaling costimulates antigen-induced Th0 and Th2 proliferation and cytokine secretion but favors a Th2-biased immune response. In the absence of antigenic stimulation, it can still induce T cell expression of IL-13. CD30 contributes to thymic negative selection by inducing the apoptotic cell death of CD4+CD8+ T cells. In B cells, CD30 ligation promotes cellular proliferation and antibody production in addition to the expression of CXCR4, CCL3, and CCL5. An 85-90 kDa soluble form of CD30 is shed from the cell surface by TACE-mediated cleavage. Soluble CD30 retains the ability to bind CD30 Ligand and functions as an inhibitor of normal CD30 signaling.
